All Publications
Publications of the year [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] [all]
| 1 | Rammensee, H. G., Z. A. Nagy, and J. Klein. 1982. Suppression of cell-mediated lymphocytotoxicity against minor histocompatibility antigens mediated by Lyt-1+Lyt- 2+ T cells of stimulator-strain origin. Eur. J. Immunol. 12:930-934. | |
| 2 | Rammensee, H.-G. 1982. Regulation und Effektorphase der Immunantwort gegen schwache Histokompatibilitätsantigene. Dissertation, Universität Tübingen. | |
| 3 | Rammensee, H. G. and J. Klein. 1983. Complexity of the histocompatibility-3 region in the mouse. J. Immunol. 130:2926-2929. | |
| 4 | Rammensee, H. G. and J. Klein. 1983. Polymorphism of minor histocompatibility genes in wild mice. Immunogenetics. 17:637-647. | |
| 5 | Rammensee, H.-G. 1983. Characterization of "veto" cells that cause nonresponsiveness to minor histocompatibility antigens. In Ir genes,past,present,and future. C.W. Pierce, S.E. Cullen, J.A. Kapp, B.D. Schwartz, and D.C. Shreffler, editors. The Humana Press, Clifton, New Jersey. 383-387. | |
| 6 | Klein, J., H. G. Rammensee, and Z. A. Nagy. 1983. Der Haupthistokompatibilitäts-komplex und die Unterscheidung zwischen Selbst und Fremd durch das Immunsystem (The major histocompatibility complex and self and non- self differentiation through the immune system). Naturwissenschaften. 70:265-271. | |
| 7 | Rammensee, H. G., A. Juretic, Z. A. Nagy, and J. Klein. 1984. Class I restricted interaction between suppressor and cytolytic cells in the response to minor histocompatibility antigens. J. Immunol. 132:668-672. | |
| 8 | Rammensee, H. G. and M. J. Bevan. 1984. Evidence from in vitro studies that tolerance to self antigens is MHC-restricted. Nature 308:741-744. | |
| 9 | Rammensee, H. G., P. J. Fink, and M. J. Bevan. 1984. Functional clonal deletion of class I-specific cytotoxic T lymphocytes by veto cells that express antigen. J. Immunol. 133:2390-2396. | |
| 10 | Fink, P. J., H. G. Rammensee, J. D. Benedetto, U. D. Staerz, L. Lefrancois, and M. J. Bevan. 1984. Studies on the mechanism of suppression of primary cytotoxic responses by cloned cytotoxic T lymphocytes. J. Immunol. 133:1769-1774. | |
| 11 | Fink, P. J., H. G. Rammensee, and M. J. Bevan. 1984. Cloned cytolytic T cells can suppress primary cytotoxic responses directed against them. J. Immunol. 133:1775-1781. | |
| 12 | Staerz, U. D., H. G. Rammensee, J. D. Benedetto, and M. J. Bevan. 1985. Characterization of a murine monoclonal antibody specific for an allotypic determinant on T cell antigen receptor. J. Immunol. 134:3994-4000. | |
| 13 | Rammensee, H. G., J. Lesley, I. S. Trowbridge, and M. J. Bevan. 1985. Antibodies against the transferrin receptor block the induction of cytotoxic T lymphocytes. A new method for antigen-specific negative selection in vitro. Eur. J. Immunol. 15:687-692. | |
| 14 | Rammensee, H.-G., M. J. Bevan, and M. J. Fink. 1985. Antigen specific suppression of T-cell responses - the veto concept. Immunol. Today 6:41-43. | |
| 15 | Rammensee, H.-G., P. J. Fink, and M. J. Bevan. 1985. The veto concept: An economic system for maintaining self tolerance of cytotoxic T lymphocytes. Transplantation Proceedings 17:689-692. | |
| 16 | Rammensee, H. G., P. J. Robinson, A. Crisanti, and M. J. Bevan. 1986. Restricted recognition of beta 2-microglobulin by cytotoxic T lymphocytes. Nature 319:502-504. | |
| 17 | Rammensee, H. G. 1986. Both parents as donors in bone marrow transplantation? Lancet 2:37-38. | |
| 18 | Matzinger, P., M. Flajnik, H.-G. Rammensee, B. Stockinger, A. G. Rolink, and L. Nicklin. 1986. The Tolerance Workshop Vol.1-3. Editiones Roche, Basel. | |
| 19 | Trowbridge, I. S., J. F. Lesley, D. Domingo, R. Schulte, C. Sauvage, and H. G. Rammensee. 1987. Monoclonal antibodies to transferrin receptor and assay of their biological effects. Methods. Enzymol. 147:265-279. | |
| 20 | Rammensee, H. G. and M. J. Bevan. 1987. Mutual tolerization of histoincompatible lymphocytes. Eur. J. Immunol. 17:893-895. | |
| 21 | Rammensee, H. G., M. H. Julius, D. Nemazee, J. Langhorne, R. Lamers, and G. Koehler. 1987. Targeting cytotoxic T cells to antigen-specific B lymphocytes. Eur. J. Immunol. 17:433-436. | |
| 22 | Rammensee, H.-G. 1987. Control of self reactive CTL independent of thymic selection. In H-2 antigens. C.S. David, editor. Plenum Publishing Corporation, 409-413. | |
| 23 | Pelkonen, J., P. Sideras, H. G. Rammensee, K. Karjalainen, and R. Palacios. 1987. Thymocyte clones from 14-day mouse embryos. I. State of T cell receptor genes, surface markers, and growth requirements. J. Exp. Med. 166:1245-1258. | |
| 24 | Julius, M.H., H.-G. Rammensee, M.J.H. Ratcliffe, M.C. Lamers, J. Langhorne, and G. Köhler. 1987. Why cognate Th-B interaction usually limits the activation of resting B cells. In The T cell receptor. J. Kappler and M. Davis, editors. A.R.Liss Inc. New York. 118-136. | |
| 25 | von Boehmer, H., K. Karjalainen, J. Pelkonen, P. Borgulya, and H. G. Rammensee. 1988. The T-cell receptor for antigen in T-cell development and repertoire selection. Immunol. Rev. 101:21-37. | |
| 26 | Rammensee, H.-G. 1988. Control of lethal autoreactivity without a network. In Theoretical Immunology, Part Two, SFI Studies in the Sciences of Complexity. A.S. Perelson, editor. Addison-Wesley Publishing Company, New York. 207-212. | |
| 27 | Rammensee, H.-G. 1988. Monoclonal antibodies from humans (Book review). Genetica 76:231-232. | |
| 28 | Rammensee, H.-G. and U. Theopold. 1988. b2-microglobulin and b-galactosidase. A real and a surrogate minor histocompatibility antigen. In MHC + X complex formation and antibody induction. Ivanyi.P. editor. Springer-Verlag, Berlin. 140-148. | |
| 29 | Rammensee, H.-G. 1988. Control of self reactive cytotoxic T lymphocytes. In Topics in immunology. F. Aiuti, L. Bonomo, and G. Daniels, editors. Il Pensiero Scientifico Editore, Rome. 250-259. | |
| 30 | Rammensee, H.-G. 1988. GVHD protection and I-J: Manifestations of specificity-related T-cell determinants. Immunol. Today 9:70-72. | |
| 31 | Julius, M. H., H. G. Rammensee, M. J. Ratcliffe, M. C. Lamers, J. Langhorne, and G. Koehler. 1988. The molecular interactions with helper T cells which limit antigen-specific B cell differentiation. Eur. J. Immunol. 18:381-386. | |
| 32 | Julius, M. H. and H. G. Rammensee. 1988. T helper cell-dependent induction of resting B cell differentiation need not require cognate cell interactions. Eur. J. Immunol. 18:375-379. | |
| 33 | Rammensee, H.-G. 1989. Cell surface antigen Thy-1 (book review). Immunogenetics 30:314 | |
| 34 | Rammensee, H.-G., H. Schild, and U. Theopold. 1989. Protein-specific cytotoxic T lymphocytes. Recognition of transfectants expressing intracellular, membrane-associated, or secreted forms of b-galactosidase. Immunogenetics 30:296-302. | |
| 35 | Rammensee, H.-G. R. Kroschewski, and B. Frangoulis. 1989. Clonal anergy induced in mature Vb6+ T lymphocytes on immunizing Mls-1b mice with Mls-1a expressing cells. Nature 339:541-544. | |
| 36 | Rammensee, H.-G. and D. Hügin. 1989. Masking of veto function in vivo by activated CD4+ T lymphocytes. Eur. J. Immunol. 19:643-648. | |
| 37 | Rammensee, H.-G. 1989. Veto in vitro and in vivo. Intern.Rev.Immunol. 4:175-191. | |
| 38 | Lenz, A., C. Heufler, H.-G. Rammensee, H. Glassl, F. Koch, N. Romani, and G. Schuler. 1989. Murine epidermal Langerhans cells express significant amounts of class I major histocompatibility complex antigens. Proc. Natl. Acad. Sci. USA 86:7527-7531. | |
| 39 | Frangoulis, B., M. Pla, and H. G. Rammensee. 1989. Alternative T cell receptor gene usage induced by self tolerance. Eur. J. Immunol. 19:553-555. | |
| 40 | Deres, K., H. Schild, K.-H. Wiesmüller, G. Jung, and H.-G. Rammensee. 1989. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 342:561-564. | |
| 41 | Wallny, H.-J. and H.-G. Rammensee. 1990. Identification of classical minor histocompatibility antigen as cell-derived peptide. Nature 343:275-278. | |
| 42 | Schild, H., O. Rötzschke, H. Kalbacher, and H.-G. Rammensee. 1990. Limit of T cell tolerance to self proteins by peptide presentation. Science 247:1587-1589. | |
| 43 | Rötzschke, O., K. Falk, H.-J. Wallny, S. Faath, and H.-G. Rammensee. 1990. Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y. Science 249:283-287. | |
| 44 | Rötzschke, O., K. Falk, K. Deres, H. Schild, M. Norda, J. Metzger, G. Jung, and H.-G. Rammensee. 1990. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 348:252-254. | |
| 45 | Rammensee, H.G. 1990. Immunregulation,Selbsttoleranz und Autoimmunität. In Studienbrief Immunologie. E. Rottländer, editor. Deutsches Institut fur Fernstudien, Tubingen,in press. | |
| 46 | Rammensee, H.-G. and D. Hügin. 1990. Elimination of self-reactive CD8+, but not CD4+, T cells by a peripheral immune mechanism. Transplantation 49:565-571. | |
| 47 | Falk, K., O. Rötzschke, and H.-G. Rammensee. 1990. Cellular peptide composition governed by major histocompatibility complex class I molecules. Nature 348:248-251. | |
| 48 | Schild, H., K. Deres, K.-H. Wiesmüller, G. Jung, and H.-G. Rammensee. 1991. Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells. Eur. J. Immunol. 21:2649-2654. | |
| 49 | Schild, H., M. Norda, K. Deres, K. Falk, O. Rötzschke, K.-H. Wiesmüller, G. Jung, and H.-G. Rammensee. 1991. Fine specifity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopetide vaccine or primed in vitro with peptide. J. Exp. Med. 174:1665-1668. | |
| 50 | Rötzschke, O., K. Falk, S. Stevanovic, G. Jung, P. Walden, and H. G. Rammensee. 1991. Exact prediction of a natural T cell epitope. Eur. J. Immunol. 21:2891-2894. | |
| 51 | Rötzschke, O., K. Falk, S. Faath, and H.-G. Rammensee. 1991. On the nature of peptides involved in T cell alloreactivity. J. Exp. Med. 174:1059-1071. | |
| 52 | Rammensee, H.-G. 1991. Wie virusinfizierte und neoblastische Zellen gezielt eliminiert werden. Aerzte Zeitung 192:12 | |
| 53 | Rammensee, H.-G. 1991. Maintenance of self tolerance in CD4+ T lymphocytes by antigen presentation on resting B cells - a hypothesis. Bone Marrow Transplant. 7, Suppl. 1:26-28. | |
| 54 | Griem, P., H.-J. Wallny, K. Falk, O. Rötzschke, B. Arnold, G. Schönrich, G. Hämmerling, and H.-G. Rammensee. 1991. Uneven tissue distribution of minor histocompatibility proteins versus peptides is caused by MHC expression. Cell 65:633-640. | |
| 55 | Falk, K., O. Rötzschke, S. Stevanovic, G. Jung, and H.-G. Rammensee. 1991. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290-296. | |
| 56 | Falk, K., O. Rötzschke, K. Deres, J. Metzger, G. Jung, and H.-G. Rammensee. 1991. Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast. J. Exp. Med. 174:425-434. | |
| 57 | Cerundolo, V., T. Elliott, J. Elvin, J. Bastin, H. G. Rammensee, and A. Townsend. 1991. The binding affinity and dissociation rates of peptides for class I major histocompatibility complex molecules. Eur. J. Immunol. 21:2069-2075. | |
| 58 | Zimmermann, N., O. Rötzschke, K. Falk, D. Rognan, G. Folkers, H. G. Rammensee, and G. Jung. 1992. Molecular modeling of the class-I human histocompatibility molecule HLA-A2 presenting an allele-specific nonapeptide from influenza matrix protein. Angewandte Chemie-International Edition in English 31:886-890. | |
| 59 | Wallny, H. J., K. Deres, S. Faath, G. Jung, A. Vanpel, T. Boon, and H. G. Rammensee. 1992. Identification and quantification of a naturally presented peptide as recognized by cytotoxic T lymphocytes specific for an immunogenic tumor variant. Int. Immunol. 4:1085-1090. | |
| 60 | Wallny, H.-J., O. Rötzschke, K. Falk, G. Hämmerling, and H.-G. Rammensee. 1992. Gene transfer experiments imply instructive role of MHC class I molecules in cellular peptide processing. Eur. J. Immunol. 22:655-659. | |
| 61 | Sekimata, M., P. Griem, K. Egawa, H. G. Rammensee, and M. Takiguchi. 1992. Isolation of human minor histocompatibility peptides. Int. Immunol. 4:301-304. | |
| 62 | Rötzschke, O., K. Falk, S. Stevanovic, G. Jung, and H.-G. Rammensee. 1992. Peptide motifs of closely related HLA class I molecules encompass substantial differences. Eur. J. Immunol. 22:2453-2456. | |
| 63 | Falk, K., O. Rötzschke, and H. G. Rammensee. 1992. Specificity of antigen processing for MHC class-I restricted presentation is conserved between mouse and man. Eur. J. Immunol. 22:1323-1326. | |
| 64 | Falk, K., O. Rötzschke, and H. G. Rammensee. 1992. A self peptide naturally presented by both H-2Kk(b) and H-2K(bm1) molecules demonstrates MHC restriction of self tolerance at the molecular level. Int. Immunol. 4:321-325. | |
| 65 | Rötzschke, O., K. Falk, S. Stevanovic, B. Grahovac, M. J. Soloski, G. Jung, and H.-G. Rammensee. 1993. Qa-2 molecules are peptide receptors of higher stringency than ordinary class I molecules. Nature 361:642-644. | |
| 66 | Rammensee, H.G., O. Rötzschke, and K. Falk. 1993. MHC Class-I-Restricted Antigen Processing - Lessons from Natural Ligands. In Naturally Processed Peptides. A. Sette, editor. Karger, 113-133. | |
| 67 | Rammensee, H. G., K. Falk, and O. Rötzschke. 1993. MHC molecules as peptide receptors. Curr. Opin. Immunol. 5:35-44. | |
| 68 | Rammensee, H.-G., K. Falk, and O. Rötzschke. 1993. Peptides naturally presented by MHC class I molecules. Ann. Rev. Immunol. 11:213-244. | |
| 69 | Rammensee, H.-G., O. Rötzschke, and K. Falk. 1993. Self tolerance of natural MHC class I ligands. Intern.Rev.Immunol. 10:291-300. | |
| 70 | Norda, M., K. Falk, O. Rötzschke, S. Stevanovic, G. Jung, and H.-G. Rammensee. 1993. Comparison of the H-2Kk and H-2Kkm1 restricted peptide motifs. J. Immunother. 14:144-149. | |
| 71 | Malcherek, G., K. Falk, O. Rötzschke, H.-G. Rammensee, S. Stevanovic, V. Gnau, G. Jung, and A. Melms. 1993. Natural peptide ligand motifs of two HLA molecules associated with myasthenia gravis. Int. Immunol. 5:1229-1237. | |
| 72 | Lopez, J. A., J. H. Lebowitz, S. M. Beverley, H. G. Rammensee, and P. Overath. 1993. Leishmania-mexicana promastigotes induce cytotoxic T lymphocytes in vivo that do not recognize infected macrophages. Eur. J. Immunol. 23:217-223. | |
| 73 | Harpur, A. G., A. Ziemiecki, A. F. Wilks, K. Falk, O. Rötzschke, and H. G. Rammensee. 1993. A prominent natural H-2 K(d) ligand is derived from protein-tyrosine kinase JAK1. Immunology Letters 35:235-238. | |
| 74 | Falk, K., O. Rötzschke, S. Faath, S. Goth, I. Graef, N. Shastri, and H. G. Rammensee. 1993. Both human and mouse cells expressing H-2K(b) and ovalbumin process the same peptide, SIINFEKL. Cell Immunol. 150:447-452. | |
| 75 | Falk, K., O. Rötzschke, B. Grahovac, D. Schendel, S. Stevanovic, G. Jung, and H. G. Rammensee. 1993. Peptide motifs of HLA-B35 and HLA-B37 molecules. Immunogenetics 38:161-162. | |
| 76 | Falk, K., O. Rötzschke, B. Grahovac, D. Schendel, S. Stevanovic, V. Gnau, G. Jung, J. L. Strominger, and H.-G. Rammensee. 1993. Allele-specific peptide ligand motifs of HLA-C molecules. Proc. Natl. Acad. Sci. USA 90:12005-12009. | |
| 77 | Deres, K., W. Beck, S. Faath, G. Jung, and H. G. Rammensee. 1993. MHC/Peptide Binding Studies Indicate Hierarchy of Anchor Residues. Cell Immunol. 151:158-167. | |
| 78 | Wölfel, T., J. Schneider, K.-H. Meyer zum Büschenfelde, H.-G. Rammensee, O. Rötzschke, and K. Falk. 1994. Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA-A2.1. Int. J. Cancer 57:413-418. | |
| 79 | Vogt, A. B., H. Kropshofer, H. Kalbacher, M. Kalbus, H. G. Rammensee, J. E. Coligan, and R. Martin. 1994. Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. J Immunol 153:1665-1673. | |
| 80 | Stevanovic, S. and H.-G. Rammensee. 1994. Novel strategies for vaccination and perspectives for immune intervention. Behring Inst. Mitt. 95:7-13. | |
| 81 | Staege, M. S., T. Dick, R. Ertl, U. Jahnel, H. Nawrath, H.-G. Rammensee, and A. B. Reske-Kunz. 1994. The antigen self-presentation function of the cytotoxic T-cell clone 10BK.1 depends on reciprocal peptide presentation. Immunology 81:333-337. | |
| 82 | Rötzschke, O., K. Falk, S. Stevanovic, V. Gnau, G. Jung, and H.-G. Rammensee. 1994. Dominant aromatic/aliphatic C-terminal anchor in HLA-B*2702 and B*2705 peptide motifs. Immunogenetics 39:74-77. | |
| 83 | Rammensee, H.-G. 1994. Wirkungsweise des Immunsystems bei intrazellulären Krankheitserregern. Naturwissenschaftliche Rundschau | |
| 84 | Rammensee, H.-G. 1994. How the quest to identify minor histocompatibility antigens led to something more important. Behring Inst. Mitt. 94:11-16. | |
| 85 | Rammensee, H.-G. 1994. Wie das Immunsystem das Innere von Zellen kontrolliert. RoKoch Mitt. 18:37-46. | |
| 86 | Rammensee, H.-G. and J. Monaco. 1994. Peptimmunology. Curr. Opin. Immunol. 6:1-2. | |
| 87 | Malcherek, G., V. Gnau, S. Stevanovic, H. G. Rammensee, C. Jung, and A. Melms. 1994. Analysis of allele-specific contact sites of natural HLA- DR17 ligands. J Immunol 153:1141-1149. | |
| 88 | Maier, R., K. Falk, O. Rötzschke, B. Maier, V. Gnau, S. Stevanovic, G. Jung, H. G. Rammensee, and A. Meyerhans. 1994. Peptide motifs of HLA-A3, -A24, and -B7 molecules as determined by pool sequencing. Immunogenetics 40:306-308. | |
| 89 | Falk, K., O. Rötzschke, M. Takiguchi, B. Grahovac, V. Gnau, S. Stevanovic, G. Jung, and H. G. Rammensee. 1994. Peptide motifs of HLA-A1, -A11, -A31, and -A33 molecules. Immunogenetics 40:238-241. | |
| 90 | Falk, K., O. Rötzschke, S. Stevanovic, V. Gnau, K. Sparbier, G. Jung, H. G. Rammensee, and P. Walden. 1994. Analysis of a naturally occurring HLA class I-restricted viral epitope. Immunology 82:337-342. | |
| 91 | Falk, K., O. Rötzschke, S. Stevanovic, G. Jung, and H. G. Rammensee. 1994. Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules. Immunogenetics 39:230-242. | |
| 92 | Sidney, J., M. F. Delguercio, S. Southwood, V. H. Engelhard, E. Appella, H. G. Rammensee, K. Falk, O. Rötzschke, M. Takiguchi, R. T. Kubo, H. M. Grey, and A. Sette. 1995. Several HLA alleles share overlapping peptide specificities. J Immunol 154:247-259. | |
| 93 | Schild, H., U. Gruneberg, G. Pougialis, H. J. Wallny, W. Keilholz, S. Stevanovic, and H. G. Rammensee. 1995. Natural ligand motifs of H-2E molecules are allele specific and illustrate homology to HLA-DR molecules. Int. Immunol. 7:1957-1965. | |
| 94 | Rammensee, H. G. 1995. Chemistry of peptides associated with MHC class I and class II molecules. Curr. Opin. Immunol 7:85-96. | |
| 95 | Rammensee, H.-G., T. Friede, and S. Stevanovic. 1995. MHC ligands and peptide motifs. First listing. Immunogenetics 41:178-228. | |
| 96 | Pomer, S., S. Stevanovic, and H.-G. Rammensee. 1995. Oberflächenantigene im Nierenzellkarzinom - Präsentation von MHC I-gebundenen Selbstpeptiden. Akt. Urol. 26:45-46. | |
| 97 | Malcherek, G., V. Gnau, G. Jung, H. G. Rammensee, and A. Melms. 1995. Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex-class II molecules. J Exp Med 181:527-536. | |
| 98 | Falk, K., O. Rötzschke, M. Takiguchi, V. Gnau, S. Stevanovic, G. Jung, and H. G. Rammensee. 1995. Peptide motifs of HLA-B58, B60, B61, and B62 molecules. Immunogenetics 41:165-168. | |
| 99 | Falk, K., O. Rötzschke, M. Takiguchi, V. Gnau, S. Stevanovic, G. Jung, and H. G. Rammensee. 1995. Peptide motifs of HLA-B38 and B39 molecules. Immunogenetics 41:162-164. | |
| 100 | Falk, K., O. Rötzschke, M. Takiguchi, V. Gnau, S. Stevanovic, G. Jung, and H.-G. Rammensee. 1995. Peptide motifs of HLA-B51, -B52, and -B78 molecules and implications for Behcet's disease. Int. Immunol. 7:223-228. | |
| 101 | Barouch, D., T. Friede, S. Stevanovic, L. Tussey, K. Smith, S. Rowlandjones, V. Braud, A. McMichael, and H. G. Rammensee. 1995. HLA-A2 subtypes are functionally distinct in peptide binding and presentation. J Exp Med 182:1847-1856. | |
| 102 | Bamford, A. I., A. Douglas, T. Friede, S. Stevanovic, H. G. Rammensee, and B. M. Adair. 1995. Peptide motif of a cattle MHC class I molecule. Immunol Lett. 45:129-136. | |
| 103 | Arnold, D., S. Faath, H. G. Rammensee, and H. Schild. 1995. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J Exp Med 182:885-889. | |
| 104 | Vartdal, F., B. H. Johansen, T. Friede, C. J. Thorpe, S. Stevanovic, J. E. Eriksen, K. Sletten, E. Thorsby, H. G. Rammensee, and L. M. Sollid. 1996. The peptide binding motif of the disease associated HLA-DQ (a1* 0501, b1* 0201) molecule. Eur. J. Immunol. 26:2764-2772. | |
| 105 | Tureci, O., U. Sahin, I. Schobert, M. Koslowski, H. Schmitt, H. J. Schild, F. Stenner, G. Seitz, H. G. Rammensee, and M. Pfreundschuh. 1996. The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res. 56:4766-4772. | |
| 106 | Stevanovic, S. and H.-G. Rammensee. 1996. The structure of T cell epitopes. In Structure of antigens. M.H.V. Van Regenmortel, editor. CRC Press, New York. 61-90. | |
| 107 | Steinle, A., K. Falk, O. Rötzschke, V. Gnau, S. Stevanovic, G. Jung, D. J. Schendel, and H. G. Rammensee. 1996. Motif of HLA-B*3503 peptide ligands. Immunogenetics 43:105-107. | |
| 108 | Shiga, H., T. Shioda, H. Tomiyama, Y. Takamiya, S. Oka, S. Kimura, Y. Yamaguchi, T. Gojoubori, H. G. Rammensee, K. Miwa, and M. Takiguchi. 1996. Identification of multiple HIV-1 cytotoxic T-cell epitopes presented by human leukocyte antigen B35 molecules. Aids 10:1075-1083. | |
| 109 | Schild, H. and H.-G. Rammensee. 1996. Peptide based vaccines. In Concepts in vaccine development. S.H.E. Kaufmann, editor. Walter de Gruyter, Berlin,New York. 303-325. | |
| 110 | Reizis, B., F. Mor, M. Eisenstein, H. Schild, S. Stevanovic, H. G. Rammensee, and I. R. Cohen. 1996. The peptide binding specificity of the MHC class II I-A molecule of the Lewis rat, RT1.BI. Int. Immunol. 8:1825-1832. | |
| 111 | Rammensee, H. G. 1996. Antigen presentation - recent developments. Int. Arch. Allergy Immunol. 110:299-307. | |
| 112 | Rammensee, H.-G. and K. F. Lindahl. 1996. Less scholasticism, more exact immunology: editorial overview. Current Opinion In Immunology 8:49-50. | |
| 113 | Rammensee, H.-G. 1996. Physiological function of MHC molecules. In Peptides in Immunology. C.H. Schneider, editor. John Wiley and Sons, Ltd. 39-53. | |
| 114 | Rammensee, H.-G. 1996. Information und Inquisition im Immunsystem. Forschung Frankfurt 14:7-16. | |
| 115 | Merkel, F., R. Kalluri, M. Marx, U. Enders, S. Stevanovic, G. Giegerich, E. G. Neilson, H. G. Rammensee, B. G. Hudson, and M. Weber. 1996. Autoreactive T-cells in Goodpasture's syndrome recognize the N-terminal NC1 domain on a3 type IV collagen. Kidney Int. 49:1127-1133. | |
| 116 | Mayer, S., C. Scheibenbogen, K. H. Lee, W. Keilholz, S. Stevanovic, H. G. Rammensee, and U. Keilholz. 1996. A sensitive proliferation assay to determine the specific T cell response against HLA-A2.1-binding peptides. J. Immunol. Methods 197:131-137. | |
| 117 | Lammert, E., D. Arnold, H. G. Rammensee, and H. Schild. 1996. Expression levels of stress protein gp96 are not limiting for major histocompatibility complex class I-restricted antigen presentation. Eur. J. Immunol. 26:875-879. | |
| 118 | Kikuchi, A., T. Sakaguchi, K. Miwa, Y. Takamiya, H. G. Rammensee, Y. Kaneko, and M. Takiguchi. 1996. Binding of nonamer peptides to three HLA-B51 molecules which differ by a single amino acid substitution in the A-pocket. Immunogenetics 43:268-76. | |
| 119 | Groettrup, M., A. Soza, M. Eggers, L. Kuehn, T. P. Dick, H. Schild, H.-G. Rammensee, U. H. Koszinowski, and P.-M. Kloetzel. 1996. A role for the proteasome regulator PA28a in antigen presentation. Nature 381:166-168. | |
| 120 | Friede, T., V. Gnau, G. Jung, W. Keilholz, S. Stevanovic, and H.-G. Rammensee. 1996. Natural ligand motifs of closely related HLA-DR4 molecules predict features of rheumatoid arthritis associated peptides. Biochem. Biophys. Acta 1316:85-101. | |
| 121 | Diehl, M., C. Munz, W. Keilholz, S. Stevanovic, N. Holmes, Y. W. Loke, and H. G. Rammensee. 1996. Nonclassical HLA-G molecules are classical peptide presenters. Curr. Biol. 6:305-314. | |
| 122 | Dick, T. P., T. Ruppert, M. Groettrup, P. M. Kloetzel, L. Kuehn, U. H. Koszinowski, S. Stevanovic, H. Schild, and H.-G. Rammensee. 1996. Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell 86:253-262. | |
| 123 | Undlien, D. E., T. Friede, H. G. Rammensee, G. Joner, K. Dahl Jorgensen, O. Sovik, H. E. Akselsen, I. Knutsen, K. S. Ronningen, and E. Thorsby. 1997. HLA-encoded genetic predisposition in IDDM: DR4 subtypes may be associated with different degrees of protection. Diabetes 46:143-149. | |
| 124 | Speidel, K., W. Osen, S. Faath, I. Hilgert, R. Obst, J. Braspenning, F. Momburg, G. J. Hammerling, and H. G. Rammensee. 1997. Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses. Eur. J. Immunol. 27:2391-2399. | |
| 125 | Scheibenbogen, C., K. H. Lee, S. Stevanovic, M. Witzens, M. Willhauck, V. Waldmann, H. Naeher, H. G. Rammensee, and U. Keilholz. 1997. Analysis of the T cell response to tumor and viral peptide antigens by an IFNg-ELISPOT assay. Int. J. Cancer 71:932-936. | |
| 126 | Scheibenbogen, C., K. H. Lee, S. Mayer, S. Stevanovic, U. Moebius, W. Herr, H. G. Rammensee, and U. Keilholz. 1997. A sensitive elispot assay for detection of CD8+ T lymphocytes specific for HLA class I binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clinical Cancer Research. 3:221-226. | |
| 127 | Reizis, B., H. Schild, S. Stevanovic, F. Mor, H. Rammensee, and I. R. Cohen. 1997. Peptide binding motifs of the MHC class I molecules (RT1.Al) of the Lewis rat. Immunogenetics 45:278-279. | |
| 128 | Rammensee, H.-G.. 1997. MHC ligands and peptide binding. In Immunology Methods Manual. I. Lefkovits, editor. Academic Press, London. 565-751. | |
| 129 | Rammensee, H.-G. 1997. Physiological function of MHC molecules. In Autoimmunity of the eye. M. Zierhut, M. Raizman, and H.-J. Thiel, editors. Aeolous Press, Buren, The Netherlands. 111-130. | |
| 130 | Rammensee, H.-G. 1997. Informationstransfer durch MHC-Moleküle. Biospektrum 3:35-40. | |
| 131 | Rammensee, H.-G., J. Bachmann, and S. Stevanovic. 1997. MHC ligands and peptide motifs. Landes Bioscience, Austin TX. | |
| 132 | Rammensee, H.-G. 1997. Tissue specific cytotoxic T cells produced by subtractive immunization in vitro. In In: Rammensee, H.-G., Bachmann, J. and Stevanovic, S. MHC ligands and peptide motifs. Landes Bioscience, Austin,TX. pp. 375-380. | |
| 133 | Münz, C., N. Holmes, A. King, Y. W. Loke, M. Colonna, H. Schild, and H. G. Rammensee. 1997. Human histocompatibility leukocyte antigen (HLA)-G molecules inhibit NKAT3 expressing natural killer cells. J. Exp. Med. 185:385-391. | |
| 134 | Maryanski, J. L., J. L. Casanova, K. Falk, H. Gournier, C. Jaulin, P. Kourilsky, F. A. Lemonnier, R. Luthy, H. G. Rammensee, O. Rötzschke, C. Servis, and J. A. Lopez. 1997. The diversity of antigen-specific TCR repertoires reflects the relative complexity of epitopes recognized. Hum. Immunol. 54:117-128. | |
| 135 | Lammert, E., D. Arnold, M. Nijenhuis, F. Momburg, G. J. Hammerling, J. Brunner, S. Stevanovic, H. G. Rammensee, and H. Schild. 1997. The endoplasmic reticulum-resident stress protein gp96 binds peptides translocated by TAP. Eur. J. Immunol. 27:923-927. | |
| 136 | Lammert, E., S. Stevanovic, J. Brunner, H. G. Rammensee, and H. Schild. 1997. Protein disulfide isomerase is the dominant acceptor for peptides translocated into the endoplasmic reticulum. Eur. J. Immunol. 27:1685-1690. | |
| 137 | Jochmus, I., W. Osen, A. Altmann, G. Buck, B. Hofmann, A. Schneider, L. Gissmann, and H. G. Rammensee. 1997. Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide. J. Gen. Virol. 78:1689-1695. | |
| 138 | Griffin, T. A., J. Yuan, T. Friede, S. Stevanovic, K. Ariyoshi, S. L. Rowland-Jones, H. G. Rammensee, and R. A. Colbert. 1997. Naturally occurring A pocket polymorphism in HLA-B*2703 increases the dependence on an accessory anchor residue at P1 for optimal binding of nonamer peptides. J. Immunol. 159:4887-4897. | |
| 139 | Godkin, A., T. Friede, M. Davenport, S. Stevanovic, A. Willis, D. Jewell, A. Hill, and H. G. Rammensee. 1997. Use of eluted peptide sequence data to identify the binding characteristics of peptides to the insulin-dependent diabetes susceptibility allele HLA-DQ8 (DQ 3.2). Int. Immunol. 9:905-911. | |
| 140 | Fisch, P., E. Meuer, D. Pende, S. Rothenfusser, O. Viale, S. Kock, S. Ferrone, D. Fradelizi, G. Klein, L. Moretta, H. G. Rammensee, T. Boon, P. Coulie, and P. van der Bruggen. 1997. Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human Vg9/Vd2 T cells in tumor immunity. Eur. J. Immunol. 27:3368-3379. | |
| 141 | de la Salle, H., E. Houssaint, M. A. Peyrat, D. Arnold, J. Salamero, D. Pinczon, S. Stevanovic, H. Bausinger, D. Fricker, E. Gomard, W. Biddison, P. Lehner, F. Uytdehaag, M. Sasportes, L. Donato, H. G. Rammensee, J. P. Cazenave, D. Hanau, M. M. Tongio, and M. Bonneville. 1997. Human peptide transporter deficiency: importance of HLA-B in the presentation of TAP-independent EBV antigens. J. Immunol. 158:4555-4563. | |
| 142 | Davenport, M. P., A. Godkin, T. Friede, S. Stevanovic, A. C. Willis, A. V. S. Hill, and H. G. Rammensee. 1997. A distinctive peptide binding motif for HLA-DRB1*0407, an HLA-DR4 subtype not associated with rheumatoid arthritis. Immunogenetics 45:229-232. | |
| 143 | Buseyne, F., S. Stevanovic, H. G. Rammensee, and Y. Riviere. 1997. Characterization of an HIV-1 p24gag epitope recognized by a CD8+ cytotoxic T-cell clone. Immunol. Lett. 55:145-149. | |
| 144 | Arnold, D., W. Keilholz, H. Schild, T. Dumrese, S. Stevanovic, and H. G. Rammensee. 1997. Evolutionary conserved cathepsin E substrate specificity as defined by N-terminal and C-terminal sequencing of peptide pools. Biol. Chem. 378:883-891. | |
| 145 | Arnold, D., W. Keilholz, H. Schild, T. Dumrese, S. Stevanovic, and H. G. Rammensee. 1997. Substrate specificity of cathepsins D and E determined by N-terminal and C-terminal sequencing of peptide pools. Eur. J. Biochem. 249:171-179. | |
| 146 | Arnold, D., C. Wahl, S. Faath, H. G. Rammensee, and H. Schild. 1997. Influences of transporter associated with antigen processing (TAP) on the repertoire of peptides associated with the endoplasmic reticulum-resident stress protein gp96. J. Exp. Med. 186:461-466. | |
| 147 | Stoltze, L., T.P. Dick, M. Deeg, B. Pömmerl, H.-G. Rammensee, and H. Schild. 1998. Generation of the vesicular stomatitis virus nucleoprotein cytotoxic T lymphocyte epitope requires proteasome-dependent and independent proteolytic activities. Eur. J. Immunol. 28:4029-4036. | |
| 148 | Seeger, F. H., D. Arnold, T. Dumrese, H. de la Salle, D. Fricker, H. Schild, H. G. Rammensee, and S. Stevanovic. 1998. The HLA-B*1516 motif demonstrates HLA-B-specific P2 pocket characteristics. Immunogenetics 48:156-160. | |
| 149 | Rammensee, H.-G. 1998. Informationstransfer durch MHC-Moleküle. Nova Acta Leopoldina 305:103-114. | |
| 150 | Obst, R., C. Munz, S. Stevanovic, and H. G. Rammensee. 1998. Allo- and self-restricted cytotoxic T lymphocytes against a peptide library: evidence for a functionally diverse allorestricted T cell repertoire. Eur. J. Immunol. 28:2432-2443. | |
| 151 | Nussbaum, A. K., T. P. Dick, W. Keilholz, M. Schirle, S. Stevanovic, K. Dietz, W. Heinemeyer, M. Groll, D. H. Wolf, R. Huber, H. G. Rammensee, and H. Schild. 1998. Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc. Natl. Acad. Sci. U. S. A. 95:12504-12509. | |
| 152 | Nickolaus, P., H. G. Rammensee, and R. Zawatzky. 1998. Interferon-induced expression of If-1h and If-1l alleles in Newcastle disease virus-infected mouse macrophages is associated with specific differences in viral gene transcription. J. Interferon Cytokine Res. 18:187-196. | |
| 153 | Malcherek, G., C. Wirblich, N. Willcox, H. G. Rammensee, J. Trowsdale, and A. Melms. 1998. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation. Eur. J. Immunol. 28:1524-1533. | |
| 154 | Gatfield, J., E. Lammert, P. Nickolaus, C. Münz, S. Rothenfusser, P. Fisch, S. Stevanovic, H. Schild, H.-G. Rammensee, and D. Arnold. 1998. Cell lines transfected with the TAP inhibitor ICP47 allow testing peptide binding to a variety of HLA class I molecules. Int. Immunol. 10:1665-1672. | |
| 155 | Gallimore, A., J. Hombach, T. Dumrese, H. G. Rammensee, R. M. Zinkernagel, and H. Hengartner. 1998. A protective cytotoxic T cell response to a subdominant epitope is influenced by the stability of the MHC class I/peptide complex and the overall spectrum of viral peptides generated within infected cells. Eur. J. Immunol. 28:3301-3311. | |
| 156 | Gallimore, A., T. Dumrese, H. Hengartner, R. M. Zinkernagel, and H. G. Rammensee. 1998. Protective immunity does not correlate with the hierarchy of virus- specific cytotoxic T cell responses to naturally processed peptides. J. Exp. Med. 187:1647-1657. | |
| 157 | Dumrese, T., S. Stevanovic, F. H. Seeger, N. Yamada, Y. Ishikawa, K. Tokunaga, M. Takiguchi, and H. Rammensee. 1998. HLA-A26 subtype A pockets accommodate acidic N-termini of ligands. Immunogenetics 48:350-353. | |
| 158 | Dick, T. P., S. Stevanovic, W. Keilholz, T. Ruppert, U. Koszinowski, H. Schild, and H. G. Rammensee. 1998. The making of the dominant MHC class I ligand SYFPEITHI. Eur. J. Immunol. 28:2478-2486. | |
| 159 | Dick, T. P., A. K. Nussbaum, M. Deeg, W. Heinemeyer, M. Groll, M. Schirle, W. Keilholz, S. Stevanovic, D. H. Wolf, R. Huber, H. G. Rammensee, and H. Schild. 1998. Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants. J. Biol. Chem. 273:25637-25646. | |
| 160 | Brossart, P., G. Stuhler, T. Flad, S. Stevanovic, H. G. Rammensee, L. Kanz, and W. Brugger. 1998. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 58:732-736. | |
| 161 | Böhm, C. M., M. L. Hanski, S. Stevanovic, H. G. Rammensee, H. Stein, J. Taylor-Papadimitriou, E. O. Riecken, and C. Hanski. 1998. Identification of HLA-A2-restricted epitopes of the tumor-associated antigen MUC2 recognized by human cytotoxic T cells. Int. J. Cancer 75:688-693. | |
| 162 | Yamada, N., Y. Ishikawa, T. Dumrese, K. Tokunaga, T. Juji, T. Nagatani, K. Miwa, H.-G. Rammensee, and M. Takiguchi. 1999. Role of anchor residues in peptide binding to three HLA-A26 molecules. Tissue Antigens 54:325-332. | |
| 163 | Seeger, F.H., M. Schirle, W. Keilholz, H.-G. Rammensee, and S. Stevanovic. 1999. Peptide motif of HLA-B*1510. Immunogenetics 49:996-999. | |
| 164 | Seeger, F.H., M. Schirle, J. Gatfield, D. Arnold, W. Keilholz, P. Nickolaus, H.-G. Rammensee, and S. Stevanovic. 1999. The HLA-A*6601 peptide motif: prediction by pocket structure and verification by peptide analysis. Immunogenetics 49:571-576. | |
| 165 | Schild, H., D. Arnold-Schild, E. Lammert, and H.-G. Rammensee. 1999. Stress proteins and immunity mediated by cytotoxic T lymphocytes. Curr. Opin. Immunol. 11:109-113. | |
| 166 | Rammensee, H.-G., J. Bachmann, N.P. N. Emmerich, O.A. Bachor, and S. Stevanovic. 1999. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213-219. | |
| 167 | Rammensee, H.-G. 1999. Introduction to Seminars in Immunology. Sem. Immunol. 11:373. | |
| 168 | Rammensee, H.-G. 1999. Some personal reflections on the history of minor histocompatibility research. In: Minor Histocompatibility Antigens: From the Laboratory to the Clinic (Eds.: D. Roopenian and E. Simpson). Landes Bioscience, Georgetown, Texas, pp. 27-35. | |
| 169 | Nickolaus, P., H.-G. Rammensee, and R. Zawatzky. 1999. Molecular cloning of a macrophage-derived, interferon-inducible secreted immunoglobulin-binding protein. Eur. J. Immunol. 29:1504-1512. | |
| 170 | Münz, C., S. Stevanovic, and H.-G. Rammensee. 1999. Peptide presentation and NK inhibition by HLA-G. J. Repr. Immunol. 43:139-155. | |
| 171 | Münz, C., R. Obst, W. Osen, S. Stevanovic, and H.-G. Rammensee. 1999. Alloreactivity as a source of high avidity peptide-specific human CTL. J. Immunol. 162:25-34. | |
| 172 | Münz, C., P. Nickolaus, E. Lammert, S. Pascolo, S. Stevanovic, and H.G. Rammensee. 1999. The role of peptide presentation in the physiological function of HLA-G. Sem. Cancer Biol. 9:47-54. | |
| 173 | Münz, C., U. Naumann, C. Grimmel, H.G. Rammensee, and M. Weller. 1999. TGF-b-independent induction of immunogenicity by decorin gene transfer in human malignant glioma cells. Eur. J. Immunol. 29:1032-1040. | |
| 174 | Mear, J.P., K.L. Schreiber, C. Münz, X. Zhu, S. StevanoviH.-G. Rammensee, S.L. Rowland-Jones, and R.A. Colbert. 1999. Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for ist role in susceptibility to spondyloarthropathies. J. Immunol. 163:6665-6670. | |
| 175 | Brossart, P., K.S. Heinrich, G. Stuhler, L. Behnke, V.L. Reichardt, S. Stevanovic, A. Muhm, H.G. Rammensee, L. Kanz, and W. Brugger. 1999. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93:4309-4317. | |
| 176 | Arnold-Schild, D., D. Hanau, D. Spehner, C. Schmid, H.G. Rammensee, H. de la Salle, and H. Schild. 1999. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J. Immunol. 162:3757-3760. | |
| 177 | Sun, Y., M. Song, S. Stevanovic, C. Jankowiak, A. Paschen, H.-G. Rammensee, and D. Schadendorf. 2000. Identification of a new HLA-A*0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen. Int. J. Cancer 87:399-404. | |
| 178 | Singh-Jasuja, H., R.E. Toes, P. Spee, C. Munz, N. Hilf, S.P. Schoenberger, P. Ricciardi-Castagnoli, J. Neefjes, H.-G. Rammensee, D. Arnold-Schild, and H. Schild. 2000. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J. Exp. Med. 191:1965-1974. | |
| 179 | Singh-Jasuja, H., H.U. Scherer, N. Hilf, D. Arnold-Schild, H.-G. Rammensee, R.E. Toes, and H. Schild. 2000. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur. J. Immunol. 30:2211-2215. | |
| 180 | Schmitz, M., P. Diestelkoetter, B. Weigle, F. Schmachtenberg, S. Stevanovic, D. Ockert, H.-G. Rammensee, and E.P. Rieber. 2000. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 60:4845-4849. | |
| 181 | Schirle, M., W. Keilholz, B. Weber, C. Gouttefangeas, T. Dumrese, H.-D. Becker, S. Stevanovic, and H.-G. Rammensee. 2000. Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur. J. Immunol. 30:2216-2225. | |
| 182 | Schild, H. and H.-G. Rammensee. 2000. Perfect use of imperfection. Nature 404:709-710. | |
| 183 | Obst, R., N. Netuschil, K. Klopfer, S. Stevanovic, and H.-G. Rammensee. 2000. The role of peptides in T cell alloreactivity is determined by self-major histocompatibility complex molecules. J. Exp. Med. 191:805-812. | |
| 184 | Kuttler, C., A.K. Nussbaum, T.P. Dick, H.-G. Rammensee, H. Schild, and K.P. Hadeler. 2000. An algorithm for the prediction of proteasomal cleavages. J. Mol. Biol. 298:417-429. | |
| 185 | Krausa, P., C. Munz, W. Keilholz, S. Stevanovic, E.Y. Jones, M. Browning, M. Bunce, H.-G. Rammensee, and A. McMichael. 2000. Definition of peptide binding motifs amongst the HLA-A*30 allelic group. Tissue Antigens 56:10-18. | |
| 186 | Jekle, A., R. Obst, F. Lang, H.-G. Rammensee, and E. Gulbins. 2000. CD95/CD95 ligand-mediated counterattack does not block T cell cytotoxicity. Biochem. Biophys. Res. Commun. 272:395-399. | |
| 187 | Hoerr, I., R. Obst, H.-G. Rammensee, and G. Jung. 2000. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur. J. Immunol. 30:1-7. | |
| 188 | Gouttefangeas, C. and H.-G. Rammensee. 2000. Problem solving for tumor immunotherapy. Nat. Biotechnol. 18:491-492. | |
| 189 | Gouttefangeas, C., M. Diehl, W. Keilholz, R.F. Hörnlein, S. Stevanovic, and H.-G. Rammensee. 2000. Thrombocyte HLA molecules retain nonrenewable endogenous peptides of megakaryocyte lineage and do not stimulate direct allocytotoxicity in vitro. Blood 95:3168-3175. | |
| 190 | Fisch, P., A. Moris, H.-G. Rammensee, and R. Handgretinger. 2000. Inhibitory MHC class I receptors on g/d T cells in tumour immunity and autoimmunity. Immunol. Today 21:187-191. | |
| 191 | Emmerich, N.P., A.K. Nussbaum, S. Stevanovic, M. Priemer, R.E. Toes, H.-G. Rammensee, and H. Schild. 2000. The human 26 S and 20 S proteasomes generate overlapping but different sets of peptide fragments from a model protein substrate. J. Biol. Chem. 275:21140-21148. | |
| 192 | Arnold-Schild, D., C. Kleist, M. Welschof, G. Opelz, H.-G. Rammensee, H. Schild, and P. Terness. 2000. One-step single-chain Fv recombinant antibody-based purification of gp96 for vaccine development. Cancer Res. 60:4175-4178. | |
| 193 | Schild, H., H.-G. Rammensee. 2000. Gp96-The immune system´s Swiss army knife. Nat. Immunol. 1(2): 100-101. | |
| 194 | Stoltze, L., M. Schirle, G. Schwarz, C. Schröter, M.W. Thompson, L.B. Hersh, H. Kalbacher, S. Stevanovic, H.-G. Rammensee, H. Schild. 2000. Two new proteases in the MHC class I processing pathway. Nat. Immunol. 1(5): 413-418. | |
| 195 | Singh-Jasuja, H., N. Hilf, H. U. Scherer, D. Arnold-Schild, H.-G. Rammensee, R. E. M. Toes, H. Schild. 2000. The heat shock protein pg96: a receptor-targeted cross-priming carrier and activator of dendritic cells. Cell Stress & Chaperons 5(5): 462-470. | |
| 196 | Kastrup, I.B., S. Stevanovic, G. Arsequell, G. Valencia, J. Zeuthen, H.-G. Rammensee, T. Elliott, J.S. Haurum. 2000. Lectin purified human class I MHC-derived peptides: evidence for presentation of glycopeptides in vivo. Tissue Antigens 56: 129-135. | |
| 197 | Vabulas, R.M., S. Braedel, N. Hilf, H. Singh-Jasuja, S. Herter, P. Ahmad-Nejad, C.J. Kirschning, C. da Costa, H.-G. Rammensee, H. Wagner, H. Schild. 2001. The ER-resident heat shock protein Gp96 activates dendritic cells via the TLR2/4 pathway. J. Biol. Chem. 277:20847-20853. | |
| 198 | Toes, R. E., A. K. Nussbaum, S. Degermann, M. Schirle, N. P. Emmerich, M. Kraft, C. Laplace, A Zwindermann, T. P. Dick, J. Müller, B. Schönfisch, C. Schmid, H. J. Fehling, S. Stevanovic, H.-G. Rammensee, H. Schild. 2001. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J. Exp. Med. 194(1): 1-12. | |
| 199 | Pascolo, S., M. Schirle, B. Gückel, T. Dumrese, S. Stumm, S. Kayer, A. Moris, D.Wallwiener, H.-G. Rammensee, S. Stevanovic. 2001. A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. Cancer Res. 61 (10): 4072-4077. | |
| 200 | Nussbaum, A. K., C. Kuttler, K. P. Hadeler, H.-G. Rammensee, H. Schild. 2001. PAProC: a prediction algorithm for proteasomal cleavages available on the WWW. Immunogenetics 53 (2): 87-94. | |
| 201 | Moris, A., D. Wernet, S. Stevanovic, H.-G. Rammensee. 2001. The peptide-specific alloreactive T cell repertoire varies largely between individuals and is not extented in HLA-A*0205-anti-HLA-A*0201 pairings. Int. Immunol. 13 (7): 863-870. | |
| 202 | Moris, A., V. Teichgräber, L. Gauthier, H. J. Buhring, H.-G. Rammensee. 2001. Cutting Edge: Characterization of allorestricted and peptide-selective alloreactive T cells using HLA-tetramer selection. J. Immunol. 166 (8): 4818-4821. | |
| 203 | Montag, S., M. Frank, H. Ulmer, D. Wernet, W. Göpel, H.-G. Rammensee. 2001. Electronic nose detects major histocompatibility complex-dependent prerenal and postrenal odor components. Proc. Natl. Acad. Sci. USA 98 (16): 9249-9254. | |
| 204 | Lang, K. S., C. C. Caroli, A. Muhm, D. Wernet, A. Moris, B. Schittek, E. Knauss-Scherwitz, S. Stevanovic, H.-G. Rammensee, C. Garbe. 2001. HLA-A2 restricted, melanocyte-specific CD8+ T lymphocytes detected in Vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. J. Invest. Dermatol. 116 (6): 891-897. | |
| 205 | Kleihauer, A., U. Grigoleit, H. Hebart, A. Moris, P. Brossart, A. Muhm, S. Stevanovic, H.-G. Rammensee, C. Sinzger, S. Riegler, G. Jahn, L. Kanz, H. Einsele. 2001. Ex vivo generation of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells. Brit. J. Haematol. 113: 231-239. | |
| 206 | Kalbus, M, B. T. Fleckenstein, M. Offenhausser, M. Bluggel, A. Melms, H. E. Meyer, H.-G. Rammensee, R. Martin, G. Jung, N. Sommer. 2001. Ligand motif of the autoimmune disease-associated mouse MHC-class II molecule H2-A(s). Eur. J. Immunol. 31 (2): 551-562. | |
| 207 | Jung, G., L. Grosse-Hovest, P. H. Krammer, H.-G. Rammensee. 2001. Target cell-restricted triggering of the CD95 (APO-1/Fas) death receptor with bispecific antibody fragments. Cancer Res. 61 (5): 1846-1848. | |
| 208 | Gouttefangeas, C., M. Eberle, P. Ruck, M. Stark, J. E. Müllers, H.-D. Becker, H.-G. Rammensee, J. Pinocy. 2001. Functional T lymphocytes infiltrate implanted polyvinyl alcohol foams during surgical wound closure therapy. Clin. Exp. Immunol. 124: 398-405. | |
| 209 | Yoshida, K., T. Martin, K. Yamamoto, C. Dobbs, C. Munz, N. Kamikawaji, N. Nakano, H.G. Rammensee, T. Sasazuki, K. Haskins, H. Kikutani. 2002. Evidence for shared recognition of a peptide ligand by a diverse panel of non-obese, diabetic mice-derived, islet-specific, diabetogenic T cell clones. Int. Immunol. 14:1439-1447. | |
| 210 | Wischhusen, J., G. Jung, I. Radovanovic, C. Beier, J.P. Steinbach, A. Rimner, H. Huang, J.B. Schulz, H. Ohgaki, A. Aguzzi, H.G. Rammensee, M. Weller. 2002. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathways of human glioblastoma. Cancer Res. 62:2592-2599. | |
| 211 | Weinschenk, T., C. Gouttefangeas, M. Schirle, F. Obermayr, S. Walter, O. Schoor, R. Kurek, W. Loeser, K.-H. Bichler, D. Wernet, S. Stevanovic, H.-G. Rammensee. 2002. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 62:5818-5827. | |
| 212 | Vabulas, R.M., S. Braedel, N. Hilf, H. Singh-Jasuja, S. Herter, P. Ahmad-Nejad, C.J. Kirschning, C. Da Costa, H.G. Rammensee, H. Wagner, H. Schild. 2002. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J. Biol. Chem. 277:20847-20853 | |
| 213 | Scheibenbogen, C., Y. Sun, U. Keilholz, M. Song, S. Stevanovic, A.M. Asemissen, D. Nagorsen, E. Thiel, H.-G. Rammensee, D. Schadendorf. 2002. Identification of known and novel immunogenic T cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment. Int. J. Cancer 98:409-414. | |
| 214 | Sarén, A., S. Pascolo, S. Stevanovic, T. Dumrese, M. Puolakkainen, M. Sarvas, H.-G. Rammensee, J.M. Vuola. 2002. Identification of Chlamydia pneumoniae-derived mouse CD8 epitopes. Infect. Immun. 70:3336-3343. | |
| 215 | Sanjeevi, C.B., T.P. Lybrand, S. Stevanovic, H.-G. Rammensee. 2002. Molecular modeling of eluted peptides form DQ6 molecules (DQB1*0602 and DQB1*0604) negatively and positively associated with type 1 diabetes. Ann. N.Y. Acad. Sci. 958:317-320. | |
| 216 | Salih, H.R., H.-G. Rammensee, A. Steinle. 2002. Cutting Edge: Down-regulation of MICA on human tumors by proteolytic shedding. J. Immunol. 169:4098-4102. | |
| 217 | Rammensee, H.-G., T. Weinschenk, C. Gouttefangeas, S. Stevanovic. 2002. Towards patient-specific tumor antigen selection for vaccination. Imm. Rev. 188:164-176. | |
| 218 | Rammensee, H.-G. 2002. Survival of the fitters. Nature 419:443-445. | |
| 219 | Radsak, M.P., N. Hilf, H. Singh-Jasuja, S. Braedel, P. Brossart, H.-G. Rammensee, and H. Schild. 2002. The heat shock protein Gp96 binds to human neutrophils and monocytes and stimulates effector functions. Blood November. | |
| 220 | Munz, C., M. Hofmann, K. Yoshida, A.K. Moustakas, H. Kikutani, S. Stevanovic, G.K. Papadopoulos, H.G. Rammensee. 2002. Peptide analysis, stability studies, and structural modeling explain contradictory peptide motifs and unique properties of the NOD mouse MHC class II molecule H2-Ag7. Eur. J. Immunol. 32:2105-2116. | |
| 221 | Maier, J.T., M. Haug, J.L. Foll, H. Beck, H. Kalbacher, H.G. Rammensee, G.E. Dannecker. 2002. Possible association of non-binding of HSP70 to HLA-DRB1 peptide sequences and protection from rheumatoid arthritis. Immunogenetics 54:67-73. | |
| 222 | Lang, K.S., A. Moris, C. Gouttefangeas, S. Walter, V. Teichgräber, M. Müller, D. Wernet, K. Hamprecht, H.-G. Rammensee, S. Stevanovic. 2002. High frequency of HCMV-specific CD8+ T cells detected in a healthy CMV-seropositive donor. Cell. Mol. Life Sci. 59:1076-1080. | |
| 223 | Lang, K.S., S. Fillon, D. Schneider, H.G. Rammensee, F. Lang. 2002. Stimulation of TNF alpha expression by hyperosmotic stress. Pflugers Arch. 443:798-803. | |
| 224 | Kircher, B., S. Stevanovic, M. Urbanek, A. Mitterschiffthaler, H.-G. Rammensee, K. Grünewald, G. Gastl, D. Nachbaur. 2002. Induction of HA-1-specific cytotoxic T cell clones parallels the therapeutic effect of donor lymphocyte infusion (DLI). Br. J. Haematol. 117:935-939. | |
| 225 | Hilf, N., H. Singh-Jasuja, P. Schwarzmaier, C. Gouttefangeas, H.G. Rammensee, H. Schild. 2002. Human platelets express heat shock protein receptors and regulate dendritic cell maturation. Blood 15:3676-3682. | |
| 226 | Hebart, H., S. Daginik, S. Stevanovic, U. Grigoleit, A. Dubler, M. Zink, C. Sinzger, G. Jahn, J. Loeffler, L. Kanz, H.-G. Rammensee, H. Einsele. 2002. Sensitive detection of HCMV peptide-specific CTL-responses by INF-g ELISPOT and flow cytometry in healthy individuals and patients after allogeneic stem cell transplantation. Blood 99:3830-3837. | |
| 227 | Einsele, H., E. Roosnek, N. Rufer, C. Sinzger, S. Riegler, J. Loffler, U. Grigoleit, A. Moris, H.G. Rammensee, L. Kanz, A. Kleihauer, F. Frank, G. Jahn, H. Hebart. 2002. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99:3916-3922. | |
| 228 | Ayyoub, M., S. Stevanovic, U. Sahin, P. Guillaume, C. Servis, D. Rimoldi, D. Valmori, P. Romero, J.-C. Cerottini, H.-G. Rammensee, M. Pfreundschuh, D. Speiser, F. Levy. 2002. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J. Immunol. 168:1717-1722. | |
| 229 | Welte, S.A., C. Sinzger, S.Z. Lutz, H. Singh-Jasuja, K.L. Sampaio, U. Eknigk, H.-G. Rammensee, A. Steinle. 2003. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur. J. Immunol. 33:194-203. | |
| 230 | Walter, S., L. Herrgen, O. Schoor, G. Jung, D. Wernet, H.J. Bühring, H.-G. Rammensee, S. Stevanovic. 2003. Cutting Edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC/anti-CD28-coated microspheres. J. Immunol. 171:4974-4978 | |
| 231 | Wagner, C., F. Neumann, B. Kubuschok, E. Regitz, A. Mischo, S. Stevanovic, M. Friedrich, W. Schmidt, H.-G. Rammensee, M. Pfreundschuh. 2003. Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2. Cancer Immunity 3:18-33. | |
| 232 | Stoltze, L., H. Rezaei, G. Jung, J. Crosclaude, P. Debey, H. Schild, H.G. Rammensee. 2003. CD4+ T-cell mediated immunity against prion proteins. Cell Mol. Life Sci. 60:629-638. | |
| 233 | Schoor, O., T. Weinschenk, J. Hennenlotter, S. Corvin, A. Stenzl, H.-G. Rammensee, S. Stevanovic. 2003. Moderate degradation does not preclude microarray analysis of small amounts of RNA. BioTechniques 35:xxx-xxx. | |
| 234 | Salih, H.R., H. Antropius, F. Gieseke, S.Z. Lutz, L. Kanz, H.-G. Rammensee, A. Steinle. 2003. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102:1389-1396. | |
| 235 | Rammensee, H.-G., N. Emmerich. 2003. Short peptides as novel therapeutics for the treatment of cancer. Business Briefing: Future Drug Discovery: 84-86. | |
| 236 | Rammensee, H.-G. 2003. Chairs Introduction. In: Novartis Foundation Symposium 254:1-2. Immunoinformatics: Bioinformatic Strategies for Better Understanding of Immune Function. Wiley, New York. | |
| 237 | Radsak, M.P. N. Hilf, H. Singh-Jasuja, S. Braedel, P. Brossart, H.-G. Rammensee, H. Schild. 2003. The heat shock protein Gp96 binds to human neutrophils and monocytes and stimulates effector functions. Blood 101: 2810-2815. | |
| 238 | Lemmel, C., H.-G. Rammensee, S. Stevanovic. 2003. Peptide motif of HLA-B*5101 and the linkage to Behçets disease. In: Immunology of Behçets Disease. Eds.: M. Zierhut, S. Ohno. Swets & Zeitlinger, Lisse. | |
| 239 | Lang, K.S. C. Weigert, S. Braedel, S. Fillon, M. Palmada, E. Schleicher, H.G. Rammensee, F. Lang. 2003. Inhibition of interferon-gamma expression by osmotic shrinkage of periphery blood lymphocytes. Am. J. Physiol. Cell Physiol. 284:200-208. | |
| 240 | Kleist, C., D. Arnold-Schild, M. Welschof, M. Finger, G. Opelz, H.G. Rammensee, H. Schild, P. Terness. 2003. Single-chain Fv-based affinity purification of the cellular stress protein gp96 for vaccine development. In: Methods Mol. Biol. 207:393-420. Recombinant Antibodies for Cancer Therapy. Ed.: M. Welschof, J. Krauss. Humana Press. | |
| 241 | Huebener, N., B. Lange, C. Lemmel, H.-G. Rammensee, A. Strandsby, J. Wenkel, J. Jikai, Y. Zeng, G. Gaedicke, H.N. Lode. 2003. Vaccination with minigenes encoding for novel self antigens are effective in DNA-vaccination against neuroblastoma. 2003. Cancer Lett 197:211-217. | |
| 242 | Hebart, H., G. Rauser, S. Stevanovic, C. Haenle, A.K. Nussbaum, C. Meisner, A.L. Bissinger, S. Tenzer, G. Jahn, J. Loeffler, H.G. Rammensee, H. Schild, H. Einsele. 2003. A CTL epitope from human cytomegalovirus IE1 defined by combining prediction of HLA binding and proteasomal processing ist he target of dominant immune responses in patients after allogeneic stem cell transplantation. Exp. Hematol. 31:966-973. | |
| 243 | Grosse-Hovest, L., I. Hartlapp, W. Marwan, G. Brem, H.-G. Rammensee, G. Jung. 2003. A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing. Eur. J. Immunol. 33:1334-1340. | |
| 244 | Friese, M.A., M. Platten, Stefan Z. Lutz, U. Naumann, S. Aulwurm, F. Bischof, H.-J. Bühring, J. Dichgans, H.-G. Rammensee, A. Steinle, M. Weller. 2003. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res. 63:8996-9006. | |
| 245 | Drexler, I., C. Staib, W. Kastenmuller, S. Stevanovic, B. Schmidt, F.A. Lemonnier, H.G. Rammensee, D.H. Busch, H. Bernhard, V. Erfle, G. Sutter. 2003. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc. Natl. Acad. Sci. USA 100:217-222. | |
| 246 | Decker, P., H. Wolburg, H.-G. Rammensee. 2003. Nucleosomes induce lymphocyte necrosis. Eur. J. Immunol. 7:1978-1987. | |
| 247 | Tenzer, S., L. Stoltze, B. Schönfisch, J. Dengjel, M. Müller, S. Stevanovic, H.-G. Rammensee, H. Schild. 2004. Quantitative analysis of prion-protein degradation by constitutive and immuno-20S proteasomes indicates differences correlated with disease susceptibility. J. Immunol. 172:1083-1091. | |
| 248 | Singh-Jasuja, H., N.P. Emmerich, H.-G. Rammensee. 2004. The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol. Immunother. 3:187-195. | |
| 249 | Schmidt, S.M., K. Schag, M.R. Muller, T. Weinschenk, S. Appel, O. Schoor, M.M. Weck, F. Grunebach, L. Kanz, S. Stevanovic, H.-G. Rammensee, P. Brossart. 2004. Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res. 3:1164-1170. | |
| 250 | Scheel, B., S. Braedel, J. Probst, J.-P. Carralot, H. Wagner, H. Schild, G. Jung, H.-G. Rammensee, S. Pascolo. 2004. Immunostimulating capacities of stabilized RNA molecules. Eur. J. Immunol. 34:537-547. | |
| 251 | Schag, K., S.M. Schmidt, M.R. Muller, T. Weinschenk, S. Appel, M.M. Weck, F. Grunebach, S. Stevanovic, H.G. Rammensee, P. Brossart. 2004. Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Clin. Cancer Res. 10:3658-3666. | |
| 252 | Rammensee, H.-G. 2004. New and Views: Immunology: Protein surgery. Nature 427:203-204. | |
| 253 | Radsak, M.P., H.R. Salih, H.-G. Rammensee, H. Schild. 2004. Triggering receptor expressed on myeloid cells-1 in neutrophil inflammatory responses: differential regulation of activation and survival. J. Immunol. 172:4956-4963 | |
| 254 | Neumann, F., C. Wagner, B. Kubuschok, S. Stevanovic, H.-G. Rammensee, M. Pfreundschuh. 2004. Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes. Cancer Immunol. Immunother 53:589-599. | |
| 255 | Lemmel, C., S. Weik, U. Eberle, J. Dengjel, T. Kratt, H.-D. Becker, H.-G. Rammensee, S. Stevanovic. 2004. Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. Nat. Biotechnol. 4:450-454. | |
| 256 | Kircher, B., M. Wolf, S. Stevanovic, H.-G. Rammensee, B. Grubeck-Loebenstein, G. Gastl, D. Nachbaur. 2004. Hematopoetic lineage-restricted minor histocompatibility antigen HA-1 graft-versus-leukemia activity after donor lymphocyte infusion. J. Immunother. 2:156-160. | |
| 257 | Hofmann, M., M. Radsak, G. Rechtsteiner, K. Wiemann, M. Günder, U. Bien-Gräter, R. Offringa, R.E.M. Toes, H.-G. Rammensee, H. Schild. 2004. T cell avidity determines the level of CTL activation. Eur. J. Immunol. 34:1798-1806. | |
| 258 | Wiemann, K., H.W. Mittrücker, U. Feger, S.A. Welte, W.M. Yokoyama, T. Spies, H.-G. Rammensee, A. Steinle. 2005. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J. Immunol. 175:720-729. | |
| 259 | Walter, S., G. Bioley, H.J. Bühring, S. Koch, D. Wernet, A. Zippelius, G. Pawelec, P. Romero, S. Stevanovic, H.-G. Rammensee, C. Gouttefangeas. 2005. High frequencies of functionally impaired cytokeratin 18-specific CD8+ T cells in healthy HLA-A2+ donors. Eur. J. Immunol. 35:2876-2885. | |
| 260 | Teufel, R., J.-P. Carralot, B. Scheel, J. Probst, S. Walter, G. Jung, I. Hörr, H.-G. Rammensee, S. Pascolo. 2005. Human peripheral blood mononuclear cells transfected with messenger RNA stimulate antigen-specific cytotoxic T lymphocytes in vitro. Cell Mol. Life Sci. 62:1755-1762. | |
| 261 | Tenzer, S., B. Peters, S. Bulik, O. Schoor, C. Lemmel, M.M. Schatz, P.M. Kloetzel, H.-G. Rammensee, H. Schild, H.G. Holzhütter. 2005. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol. Life Sci. 62:1025-1037. | |
| 262 | Tammiruusu, A., A. Haveri, S. Pascolo, R. Lahesmaa, S. Stevanovic, H.-G. Rammensee, M. Sarvas, M. Puolakkainen, J.M. Vuola. 2005. Clearance of Chlamydia pneumoniae infection in H-2 class I-/- human leucocyte antigen-A2.1 monochain transgenic mice. Scand. J. Immunol. 62:131-139. | |
| 263 | Schuler, M.M., P. Donnes, M.-D. Nastke, O. Kohlbacher, H.-G. Rammensee, S. Stevanovic. 2005. SNEP: SNP-derived epitope prediction program for minor H antigens. Immunogenetics 57:816-820. | |
| 264 | Schilbach, K., G. Kerst, S. Walter, M. Eyrich, D. Wernet, R. Handgretinger, W. Xie, H.-G. Rammensee, I. Müller, H.-J. Bühring, D. Niethammer. 2005. Cytotoxic minor histocompatibility antigen HA-1-specific CD8+ effector memory T cells: Artificial APCs pave the way for clinical application by potent primary in vitro induction. Blood 106:144-149. | |
| 265 | Scheel, B., R. Teufel, J. Probst, J.-P. Carralot, J. Geginat, M. Radsak, D. Jarrossay, H. Wagner, G. Jung, H.-G. Rammensee, I. Hörr, S. Pascolo. 2005. Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur. J. Immunol. 35:1557-1566. | |
| 266 | Ramirez, S.R., H. Singh-Jasuja, T. Warger, S. Braedel-Ruoff, N. Hilf, K. Wiemann, H.G. Rammensee, H. Schild. Glycoprotein 96-actiated dendritic cells induce a CD8-biased T-cell response. 2005. Cell Stress Chaperones 10:221-229. | |
| 267 | Pascolo, S., F. Ginhoux, N. Laham, S. Walter, O. Schoor, J. Probst, P. Rohrlich, F. Obermayr, P. Fisch, O. Danos, R. Ehrlich, F.A. Lemonnier, H.-G. Rammensee. 2005. The non-classical HLA class I molecule HFE does not influence the NK-like activity contained in fresh human PBMCs and does not interact with NK cells. Int. Immunol.17:117-122. | |
| 268 | Neumeister, B., M. Faigle, D. Spitznagel, A. Mainka, A. Ograbek, H. Wieland, N. Mannowetz, H.-G. Rammensee. 2005. Legionella pneumophila down-regulates MHC class I expression of human monocytic host cells and thereby inhibits T cell activation. Cell. Mol. Life Sci. 62:578-588. | |
| 269 | Nastke, M.-D., L. Herrgen, S. Walter, D. Wernet, H.-G. Rammensee, S. Stevanovic. 2005. Major contribution of codominant CD8 and CD4 T cell epitopes to the human cytomegalovirus-specific T cell repertoire. Cell. Mol. Life Sci. 62:77-86. | |
| 270 | Krüger, T., O. Schoor, C. Lemmel, B. Krämer, C. Reichle, J. Dengjel, T. Weinschenk, M. Müller, J. Hennenlotter, A. Stenzl, H.-G. Rammensee, S. Stevanovic. 2005. Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol., Immunother. 54:826-836. | |
| 271 | Kramer, B.F., O. Schoor, T. Kruger, C. Reichle, M. Muller, T. Weinschenk, J. Hennenlotter, A. Stenzl, H.-G. Rammensee, S. Stevanovic. 2005. MAGED4-expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligand from solid tumor tissue. Cancer Biol. Ther. 4:943-948. | |
| 272 | Jung, G., Herrmann, T., Grosse-Hovest, L., Salih, H.R., Rammensee, H.-G.: Monoclonal and bispecific antibodies as novel therapeutics. Chapter XI. In: Los, M., Gibson, S.B. (Eds) Apoptotic Pathways as Targets for Novel Therapies in Cancer and Other Diseases. Springer, Berlin, 229 242 (2005) | |
| 273 | Herter, S., P. Osterloh, N. Hilf, G. Rechtsteiner, J. Höhfeld, H.-G. Rammensee, H. Schild. 2005. Dendritic cell aggresome-like-induced structure formation and delayed antigen presentation coincide in influenza virus-infected dendritic cells. J. Immunol. 175:891-898. | |
| 274 | Grosse-Hovest, L., W. Wick, R. Minoia, M. Weller, M, H.-G. Rammensee, G. Brem, G. Jung. 2005. Supraagonistic, bispecific single-chain antibody purified from the serum of cloned, transgenic cows induces T-cell-mediated killing of glioblastoma cells in vitro and in vivo. Int. J. Cancer 117:1060-1064. | |
| 275 | Dittmann, J., K. Keller-Matschke, T. Weinschenk, T. Kratt, T. Heck, H.-D. Becker, S. Stevanovic, H.-G. Rammensee, C. Gouttefangeas. 2005. CD8+ T-cell response against MUC-1-derived peptides in gastrointestinal cancer survivors. Cancer Immunol., Immunother. 54:750-758. | |
| 276 | Dengjel, J., O. Schoor, R. Fischer, M. Reich, M. Kraus, M. Müller, K. Kreymborg, F. Altenberend, J. Brandenburg, H. Kalbacher, R. Brock, C. Driessen, H.-G. Rammensee, S. Stevanovic. 2005. Autophagy promotes MHC class II presentation of peptides form intracellular source proteins. Proc. Natl. Acad. Sci. USA 102:7922-7927. | |
| 277 | Dengjel, J., H.-G. Rammensee, S. Stevanovic. 2005. Glycan side chains on naturally presented MHC class II ligands. J. Mass Spectrom. 40:100-104. | |
| 278 | Decker, P., H. Singh-Jasuja, S. Haager, I. Kotter, H.-G. Rammensee. 2005. Nucleosome, the main autoantigen in systemic lupus erythematosus, induces direct dendritic cell activation via a MyD88-independent pathway: consequences on inflammation. J. Immunol. 174:3326-3334. | |
| 279 | Carralot, J.-P., B. Weide, O. Schoor, J. Probst, B. Scheel, R. Teufel, I. Hörr, C. Garbe, H-G. Rammensee, S. Pascolo. 2005. Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas. Genet. Vaccines Ther. 3:6. | |
| 280 | Carralot, J.-P., C. Dumrese, R. Wessel, R. Riessen, I. Autenrieth, S. Walter, O. Schoor, S. Stevanovic, H.-G. Rammensee, S. Pascolo. 2005. CD8+ T cells specific for a potential HLA-A*0201 epitope from Chlamydophila pneumoniae are present in the PBMCs from infected patients. Int. Inmunol. 17:591-597. | |
| 281 | Warger, T., N. Hilf, G. Rechtsteiner, P. Haselmayer, D.M. Carrick, H. Jonuleit, P. von Landenberg, H.-G. Rammensee, C.V. Nicchitta, M.P. Radsak, H. Schild. 2006. Interaction of TLR2 and TLR4 ligands with the N-terminal domain of GP96 amplifies innate and adaptive immune responses. J. Biol. Chem. 281:22545-22553. | |
| 282 | Scheel, B., S. Aulwurm, J. Probst, L. Stitz, I. Hoerr, H.-G. Rammensee, M. Weller, S. Pascolo. 2006. Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur. J. Immunol. 36:2807-2816. | |
| 283 | Rönnefarth, V.M., A.I.M. Erbacher, T. Lamkemeyer, J. Madlung, A. Nordheim, H.-G. Rammensee, P. Decker. 2006. TLR2/TLR4-independent neutrophil activation and recruitment upon endocytosis of nucleosomes reveals a new pathway of innate immunity in systemic lupus erythematosus. J. Immunol. 177:7740-7749. | |
| 284 | Röck, F., S. Mueller, U. Weimar, H.-G. Rammensee, P. Overath. 2006. Comparative analysis of volatile constituents from mice and their urine. J. Chem. Ecol. 32:1333-1346. | |
| 285 | Rechtsteiner, G., T. Warger, M. Hofmann, H.-G. Rammensee, H. Schild, M.P. Radsak. 2006. Precursor frequency can compensate for lower TCR expression in T cell competition during priming in vivo. Eur. J. Immunol. 36:2613-2623. | |
| 286 | Rammensee, H.-G. 2006. Some considerations on the use of peptides and mRNA for therapeutic vaccination against cancer. Immunol. Cell Biol. 84:290-294. | |
| 287 | Rammensee, H.-G. 2006. Peptides made to order. Immunity 25:693-695. | |
| 288 | Probst, J., S. Brechtel, B. Scheel, I. Hoerr, G. Jung, H.-G. Rammensee, S. Pascolo. 2006. Characterization of the ribonuclease activity on the skin surface. Genetic Vaccines Ther. 4:xxx-xxx. | |
| 289 | Osterloh, P., K. Linkemann, S. Tenzer, H.-G. Rammensee, M.P. Radsak, D.H. Busch, H. Schild. 2006. Proteasomes shape the repertoire of T cells participating in antigen-specific immune responses. Proc. Natl. Acad. Sci. USA 103:5042-5047. | |
| 290 | Falk, K., O. Rötzschke, S. Stevanovi, G. Jung, H.-G. Rammensee. 2006. Allele-specific motifs revealed by sequencing of self peptides eluted from MHC molecules. J. Immunol. 177:2741-2747. | |
| 291 | Dengjel, J., M.-D. Nastke, C. Gouttefangeas, G. Gitsioudis, O. Schoor, F. Altenberend, M. Müller, B. Krämer, A. Missiou, M. Sauter, J. Hennenlotter, D. Wernet, A. Stenzl, H.-G. Rammensee, K. Klingel, S. Stevanovic. 2006. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin. Cancer Res. 12:4163-4170. | |
| 292 | Decker, P., I. Kötter, R. Klein, B. Berner, H.-G. Rammensee. 2006. Monocyte-dervied dendritic cells over-express CD86 in patients with systemic lupus erythematosus. Rheumatology 45:1087-1095. | |
| 293 | Asemissen, A.-M., U. Keilholz, S. Tenzer, M. Müller, S. Walter, S. Stevanovic, H. Schild, A. Letsch, E. Thiel, H.-G. Rammensee, C. Scheibenbogen. 2006. identification of a highly immunogenic HLA-A*01-binding T-cell epitope of WT1. Clin. Cancer Res. 12:7476-7482. |
Publications of the year [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] [all]